Conference Coverage
Conference Coverage
HPV Vaccine Offers Cancer Protection Beyond Cervical Cancer
A ‘really important study’ extends the information about the impact of getting vaccinated against HPV, says expert.
Conference Coverage
Myeloma: VRd Plus Isatuximab Improves Outcomes
Newly diagnosed, transplant-ineligible patients with multiple myeloma fare better when standard treatment gets a boost.
Conference Coverage
T-DXd Moves Toward First Line for HER2-Low Metastatic BC
New results from DESTINY trials support use of the antibody-drug conjugate earlier in the treatment algorithm for cancers expressing even the...
Conference Coverage
MCL: Dual Therapy ‘Promising’ in Patients With TP53 mutations
Outcomes improved across cohorts when venetoclax was added to ibrutinib, new analysis of phase-3 study finds.
Conference Coverage
CAR T for B-ALL: Game Changer For Young Patients?
Survival rises as tisagenlecleucel therapy reaches those with less severe disease, displacing HSCT.
Conference Coverage
Young People’s Gut Bacteria May Drive Colorectal Cancer Risk
Researchers found signs that a high-fat, low-fiber diet may increase inflammation in the gut that prevents it from naturally suppressing tumors....
Conference Coverage
‘Practice Changing’ Results for Osimertinib in Unresectable Stage III EGFR+ NSCLC
Study results, including extended median PFS of 33.5 months, are expected to lead to approval in unresectable stage III disease.
Conference Coverage
Myeloma: First-In-Class ADC Regimen Yields Key Benefits
Patients with relapsed/refractory multiple myeloma show significant improvements in PFS when treated with an antibody-drug conjugate.
Conference Coverage
Anti-Müllerian Hormone Predicts Chemo Benefits in BC
Hormone level measures may help some patients with HR+/HER2- invasive breast cancer avoid chemotherapy.
Conference Coverage
‘Groundbreaking’ Trial Shows Survival Benefits in Lung Cancer
Presentation on treatment for limited stage small cell lung cancer draws rounds of applause at the annual meeting of the American Society of...
Feature
Should ER-Low Breast Cancer Patients Be Offered Endocrine Therapy?
New evidence suggests that omitting endocrine therapy increases the risk of death in this patient group.